AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23316894 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 10
Study 21648056 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal hot tub use during early pregnancy
Number of subjects: 10825
Study 21648056 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal hot tub use more than once and for more than 30 min
Number of subjects: 10825
Study 18646005 — intervention group
Group type: EXPERIMENTAL
Intervention: interesterified butter blend with fish oil (352 mg n‐3 long‐chain PUFA)
Number of subjects: 12
Study 18646005 — intervention group
Group type: COMPARATOR
Intervention: commercial butter blend
Number of subjects: 12
Study 16269449 — intervention group
Group type: EXPERIMENTAL
Intervention: OCP group (n = 214)
Number of subjects: 425
Study 16269449 — intervention group
Group type: COMPARATOR
Intervention: Non-OCP group (n = 211)
Number of subjects: 425
Study 12652607 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioral relaxation training groups (CBSM)
Number of subjects: 148
Study 12652607 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support groups (SSG)
Number of subjects: 148
Study 12652607 — intervention group
Group type: COMPARATOR
Intervention: WAIT‐listed control group
Number of subjects: 148
Study 10949982 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin (10 mg x kg(‐1) x d(‐1))
Number of subjects: 32
Study 10949982 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin (40 mg x kg(‐1) x d(‐1)) plus ceftazidime and netilmicin
Number of subjects: 32
Study 10949982 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin
Number of subjects: 32
Study 10949982 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 32
Study 1684749 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyldopa (500 mg to 1 g daily)
Number of subjects: 157
Study 1684749 — intervention group
Group type: COMPARATOR
Intervention: Rilmenidine (1 to 2 mg daily)
Number of subjects: 157
Study 1684749 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 157
Study 1684749 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyldopa
Number of subjects: 157
Study 1684749 — intervention group
Group type: COMPARATOR
Intervention: Rilmenidine
Number of subjects: 157
Study 6753223 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training
Number of subjects: 34
Study 6753223 — intervention group
Group type: COMPARATOR
Intervention: Control group (exercise training after control period)
Number of subjects: 34
Study 29578271 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducation (8 sessions of group-based psychoeducation)
Number of subjects: 100
Study 29578271 — intervention group
Group type: COMPARATOR
Intervention: Regular free discussions (control group)
Number of subjects: 100
Study 29390001 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic open kinetic chain stretching (DS)
Number of subjects: 36
Study 29390001 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic closed kinetic chain stretching (LEC)
Number of subjects: 36
Study 29390001 — intervention group
Group type: COMPARATOR
Intervention: Jogging only (CON)
Number of subjects: 36
Study 27135066 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsinoids
Number of subjects: 20
Study 27135066 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 24646429 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Intervention (BI) for medication-overuse headache (MOH)
Number of subjects: 6
Study 24646429 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback from GPs and patients about the feasibility and logistics of the study design, screening/recruitment process, BI and headache interviews
Number of subjects: 6
Study 22915657 — intervention group
Group type: EXPERIMENTAL
Intervention: palonosetron + dexamethasone on day 1 with prochlorperazine on days 2 and 3
Number of subjects: 234
Study 22915657 — intervention group
Group type: EXPERIMENTAL
Intervention: aprepitant + palonosetron + dexamethasone on day 1 with aprepitant + dexamethasone on days 2 and 3
Number of subjects: 234
Study 22915657 — intervention group
Group type: COMPARATOR
Intervention: granisetron + dexamethasone on day 1 with prochlorperazine on days 2 and 3
Number of subjects: 234
Study 20156957 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Strategic Family Therapy (BSFT)
Number of subjects: 1819
Study 20156957 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 1819
Study 20156957 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescents (BSFT and TAU combined)
Number of subjects: 1819
Study 20156957 — intervention group
Group type: EXPERIMENTAL
Intervention: Family members (BSFT)
Number of subjects: 1819
Study 17265549 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (manual needle stimulation of 19 acupoints, 30 min sessions, 10 sessions over a year)
Number of subjects: 34
Study 17265549 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 34
Study 17265549 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (20 non-anxious women)
Number of subjects: 34
Study 16105122 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg lansoprazole initially and maintenance therapy with a standard dose H(2)‐RA
Number of subjects: 43
Study 16105122 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg of lansoprazole initially and maintenance therapy of 15 mg lansoprazole
Number of subjects: 43
Study 16105122 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg of lansoprazole once daily for 16 weeks
Number of subjects: 43
Study 16105122 — intervention group
Group type: COMPARATOR
Intervention: Stepped down to famotidine
Number of subjects: 43
Study 12688626 — intervention group
Group type: EXPERIMENTAL
Intervention: Mite-impermeable mattress and pillow covers
Number of subjects: 4146
Study 12688626 — intervention group
Group type: COMPARATOR
Intervention: Natural history study (no specific intervention mentioned)
Number of subjects: 4146
Study 12688626 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention measure
Number of subjects: 4146
Study 10395849 — intervention group
Group type: EXPERIMENTAL
Intervention: Stavudine plus didanosine (group 1)
Number of subjects: 151
Study 10395849 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine plus lamivudine (group 2)
Number of subjects: 151
Study 10395849 — intervention group
Group type: EXPERIMENTAL
Intervention: Stavudine plus didanosine followed by zidovudine plus lamivudine (group 3)
Number of subjects: 151
Study 7569759 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 89
Study 7569759 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 2309835 — intervention group
Group type: EXPERIMENTAL
Intervention: Disopyramide
Number of subjects: 10
Study 6644887 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin with urokinase
Number of subjects: 44
Study 6644887 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin without urokinase
Number of subjects: 44
Study 6644887 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin with or without urokinase
Number of subjects: 44
Study 30478608 — intervention group
Group type: EXPERIMENTAL
Intervention: Procedural WM training
Number of subjects: 175
Study 30478608 — intervention group
Group type: COMPARATOR
Intervention: Active-control training
Number of subjects: 175
Study 30478608 — intervention group
Group type: COMPARATOR
Intervention: No-contact control
Number of subjects: 175
Study 30499443 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured lifestyle self-management education sessions (four 2.5-hour sessions, 1 week apart; multimodal fortnightly support contacts; three 2.5-hour booster sessions at 3-month intervals)
Number of subjects: 414
Study 30499443 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured lifestyle self-management education sessions
Number of subjects: 414
Study 30499443 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 414
Study 26742066 — intervention group
Group type: EXPERIMENTAL
Intervention: Low glycaemic index dietary advice during pregnancy
Number of subjects: 280
Study 26742066 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard dietary advice)
Number of subjects: 280
Study 26742066 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal dietary intake (trimester three GI, trimester two saturated fats, trimester one and three sodium)
Number of subjects: 280
Study 26742066 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal dietary intake (trimester two and three vitamin C)
Number of subjects: 280
Study 24217934 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone 30 mg/day
Number of subjects: 86
Study 24217934 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 24406355 — intervention group
Group type: EXPERIMENTAL
Intervention: High crossectomy without vascular sectioning (HCWVS)
Number of subjects: 150
Study 24406355 — intervention group
Group type: COMPARATOR
Intervention: Classic saphenectomy (CS)
Number of subjects: 150
Study 20723187 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D(3) supplementation (100,000 iu) along with antibiotics
Number of subjects: 453
Study 20723187 — intervention group
Group type: COMPARATOR
Intervention: Placebo along with antibiotics
Number of subjects: 453
Study 20723187 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D(3) supplementation
Number of subjects: 453
Study 20723187 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 453
Study 18406037 — intervention group
Group type: EXPERIMENTAL
Intervention: ACLS skills
Number of subjects: 133
Study 18406037 — intervention group
Group type: EXPERIMENTAL
Intervention: BLS skills
Number of subjects: 133
Study 16005520 — intervention group
Group type: EXPERIMENTAL
Intervention: QI-Therapy
Number of subjects: 1356
Study 16005520 — intervention group
Group type: EXPERIMENTAL
Intervention: QI-Meds
Number of subjects: 1356
Study 16005520 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 1356
Study 14629655 — intervention group
Group type: EXPERIMENTAL
Intervention: Delipidated acid-treated M. vaccae (0.4 mg first dose, 0.8 mg second dose)
Number of subjects: 37
Study 14629655 — intervention group
Group type: COMPARATOR
Intervention: Phosphate buffered saline (placebo)
Number of subjects: 37
Study 10585042 — intervention group
Group type: EXPERIMENTAL
Intervention: Antegrade cardioplegia (group 1)
Number of subjects: 75
Study 10585042 — intervention group
Group type: COMPARATOR
Intervention: Antegrade/retrograde cardioplegia (group 2)
Number of subjects: 75
Study 8760546 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygen therapy (HBO) - 100% O2 at 2.5 ata for 90 minutes, twice daily, over 6 days
Number of subjects: 36
Study 8760546 — intervention group
Group type: COMPARATOR
Intervention: Placebo - 21% O2 at 1.1 ata for 90 minutes, twice daily, over 6 days
Number of subjects: 36
Study 8760546 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygen therapy (HBO)
Number of subjects: 36
Study 8760546 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 1750819 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment (exact intervention not specified)
Number of subjects: 74
Study 1750819 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 74
Study 6217022 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium lauryl sulfate (SLS) applied in concentrations ranging from 0.001% to 5% under occlusion for 24 hours.
Number of subjects: 950
Study 6217022 — intervention group
Group type: COMPARATOR
Intervention: Visual scoring of skin irritancy reactions.
Number of subjects: 950
Study 31271608 — intervention group
Group type: COMPARATOR
Intervention: Standard urotherapy
Number of subjects: 38
Study 31271608 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard urotherapy associated with pelvic floor muscle training
Number of subjects: 38
Study 31271608 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard urotherapy associated with pelvic floor muscle training and oxybutynin
Number of subjects: 38
Study 29098247 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser as an adjunctive to scaling and root planning (SRP)
Number of subjects: 11
Study 29098247 — intervention group
Group type: COMPARATOR
Intervention: Control group (SRP only)
Number of subjects: 11
Study 27158853 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Intervention (BI)
Number of subjects: 465
Study 27158853 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 465
Study 25156568 — intervention group
Group type: EXPERIMENTAL
Intervention: High OC group
Number of subjects: 0
Study 25156568 — intervention group
Group type: COMPARATOR
Intervention: Low OC group
Number of subjects: 0
Study 25156568 — intervention group
Group type: COMPARATOR
Intervention: High trait anxiety group
Number of subjects: 0
Study 25156568 — intervention group
Group type: COMPARATOR
Intervention: Low trait anxiety group
Number of subjects: 0
Study 21911313 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy (holding ice cubes in mouth before, during, and after chemotherapy)
Number of subjects: 60
Study 21911313 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 60
Study 21911313 — intervention group
Group type: COMPARATOR
Intervention: Control (routine care)
Number of subjects: 60
Study 19434929 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose IFN‐α‐2b induction therapy combined with amantadine and ribavirin for 6 weeks followed by weekly pegylated IFN‐α‐2b for 24 or 48 weeks
Number of subjects: 31
Study 19434929 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose IFN‐α‐2b induction therapy
Number of subjects: 31
Study 17103193 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g-IVIG
Number of subjects: 109
Study 17103193 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g-IVIG
Number of subjects: 109
Study 17103193 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g-IVIG with additional IVIG
Number of subjects: 109
Study 15319712 — intervention group
Group type: COMPARATOR
Intervention: Heller myotomy
Number of subjects: 43
Study 15319712 — intervention group
Group type: EXPERIMENTAL
Intervention: Heller myotomy plus Dor fundoplication
Number of subjects: 43
Study 11429399 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone (1.5, 3, 5, 7, and 10 microM)
Number of subjects: 0
Study 11429399 — intervention group
Group type: EXPERIMENTAL
Intervention: Desethylamiodarone (primary metabolite of amiodarone)
Number of subjects: 0
Study 11429399 — intervention group
Group type: COMPARATOR
Intervention: Amiodarone (oral administration for 4 weeks)
Number of subjects: 0
Study 9599521 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide (two inhalations of 1000 micrograms)
Number of subjects: 59
Study 9599521 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular dexamethasone (0.6 mg/kg)
Number of subjects: 59
Study 8020641 — intervention group
Group type: EXPERIMENTAL
Intervention: Postprandial hypotension intervention
Number of subjects: 15
Study 8020641 — intervention group
Group type: COMPARATOR
Intervention: Control group (water only)
Number of subjects: 15
Study 2744928 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise at 40% of maximal workload with carbohydrate feeding (25% maltodextrin-fructose solution) for 2.5 hours
Number of subjects: 16
Study 2744928 — intervention group
Group type: COMPARATOR
Intervention: Rest for 2.5 hours with carbohydrate feeding (25% maltodextrin-fructose solution)
Number of subjects: 16
Study 1253811 — intervention group
Group type: EXPERIMENTAL
Intervention: Aldosterone infusion before fasting and on day 4 of fasting
Number of subjects: 32
Study 1253811 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone treatment (300 mg/day p.o.) on days 6 to 8 of the fast
Number of subjects: 32
Study 1253811 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose load (100 g) on day 7
Number of subjects: 32
Study 1253811 — intervention group
Group type: EXPERIMENTAL
Intervention: Salivary sodium output measurement
Number of subjects: 32
Study 31770449 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgeons' prediction scores based on injury and initial postoperative radiographs
Number of subjects: 95
Study 31770449 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgeons' prediction confidence level greater than 1 SD above the mean
Number of subjects: 95
Study 31770449 — intervention group
Group type: COMPARATOR
Intervention: Surgeons' prediction ability
Number of subjects: 95
Study 31770449 — intervention group
Group type: COMPARATOR
Intervention: Characteristics associated with lower prediction scores
Number of subjects: 95
Study 30648318 — intervention group
Group type: EXPERIMENTAL
Intervention: Active radiofrequency exposure
Number of subjects: 18
Study 30648318 — intervention group
Group type: COMPARATOR
Intervention: Sham exposure
Number of subjects: 18
Study 28291296 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback condition
Number of subjects: 84
Study 28291296 — intervention group
Group type: COMPARATOR
Intervention: No feedback condition
Number of subjects: 84
Study 24460000 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-hour on-the-job classroom training (Team Awareness Program and Choices in Health Promotion Program)
Number of subjects: 1510
Study 24460000 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 1510
Study 24482945 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular ACTH stimulation test using Acton Prolongatum (25 units injected intramuscularly)
Number of subjects: 150
Study 24482945 — intervention group
Group type: COMPARATOR
Intervention: Basal cortisol measurement
Number of subjects: 150
Study 24482945 — intervention group
Group type: EXPERIMENTAL
Intervention: Post ACTH serum cortisol
Number of subjects: 150
Study 24482945 — intervention group
Group type: COMPARATOR
Intervention: Basal and post ACTH serum cortisol levels in healthy adults and patients with diabetes mellitus and primary hypothyroidism
Number of subjects: 150
Study 24482945 — intervention group
Group type: COMPARATOR
Intervention: Comparison of basal cortisol levels between patients with known adrenal insufficiency and controls
Number of subjects: 150
Study 20820169 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese virtual patient
Number of subjects: 76
Study 20820169 — intervention group
Group type: COMPARATOR
Intervention: Non-obese virtual patient
Number of subjects: 76
Study 20820169 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical recommendations
Number of subjects: 76
Study 18556361 — intervention group
Group type: EXPERIMENTAL
Intervention: Medulla oblongata volume (MOV) in patients with MS
Number of subjects: 45
Study 18556361 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 45
Study 15910892 — intervention group
Group type: EXPERIMENTAL
Intervention: Ajulemic acid (AJA) 40 mg and 80 mg daily
Number of subjects: 21
Study 15910892 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 21
Study 15910892 — intervention group
Group type: EXPERIMENTAL
Intervention: Ajulemic acid (AJA)
Number of subjects: 21
Study 14522763 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral acyclovir 400 mg twice daily for 6 months
Number of subjects: 68
Study 14522763 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets for 6 months
Number of subjects: 68
Study 10945510 — intervention group
Group type: EXPERIMENTAL
Intervention: Naftidrofuryl 600 mg/d
Number of subjects: 84
Study 10945510 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 8803646 — intervention group
Group type: EXPERIMENTAL
Intervention: D-amphetamine
Number of subjects: 12
Study 8803646 — intervention group
Group type: EXPERIMENTAL
Intervention: L-fenfluramine
Number of subjects: 12
Study 8803646 — intervention group
Group type: EXPERIMENTAL
Intervention: D-fenfluramine
Number of subjects: 12
Study 8803646 — intervention group
Group type: EXPERIMENTAL
Intervention: D-amphetamine + D-fenfluramine
Number of subjects: 12
Study 8803646 — intervention group
Group type: EXPERIMENTAL
Intervention: D-amphetamine + L-fenfluramine
Number of subjects: 12
Study 8803646 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 1611459 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofragmentable anastomotic ring (Valtrac‐BAR)
Number of subjects: 150
Study 1611459 — intervention group
Group type: COMPARATOR
Intervention: Hand-suture with a two-layer anastomosis of resorbable suture material (3/0 Dexon)
Number of subjects: 150
Study 6418300 — intervention group
Group type: EXPERIMENTAL
Intervention: Real electroconvulsive therapy
Number of subjects: 138
Study 6418300 — intervention group
Group type: COMPARATOR
Intervention: Simulated electroconvulsive therapy
Number of subjects: 138
Study 6418300 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy
Number of subjects: 138
Study 31389835 — intervention group
Group type: EXPERIMENTAL
Intervention: McGrath Mac Video Laryngoscope
Number of subjects: 514
Study 31389835 — intervention group
Group type: COMPARATOR
Intervention: Direct Laryngoscopy
Number of subjects: 514
Study 31389835 — intervention group
Group type: EXPERIMENTAL
Intervention: Both devices
Number of subjects: 514
Study 31389835 — intervention group
Group type: EXPERIMENTAL
Intervention: Switching device after failed first attempt
Number of subjects: 514
Study 29127547 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium and zinc co-supplementation (250 mg of magnesium oxide plus 220 mg of zinc sulfate containing 50 mg zinc)
Number of subjects: 60
Study 29127547 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 26649759 — intervention group
Group type: COMPARATOR
Intervention: Familiar language (English)
Number of subjects: 0
Study 26649759 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfamiliar language (Spanish or Icelandic)
Number of subjects: 0
Study 26649759 — intervention group
Group type: COMPARATOR
Intervention: Both familiar and unfamiliar languages
Number of subjects: 0
Study 24949908 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavior therapy (ICBT)
Number of subjects: 0
Study 24949908 — intervention group
Group type: COMPARATOR
Intervention: Cognitive behavioral group therapy (CBGT)
Number of subjects: 0
Study 22498745 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib-thalidomide-dexamethasone (VTD)
Number of subjects: 236
Study 22498745 — intervention group
Group type: COMPARATOR
Intervention: Thalidomide-dexamethasone (TD)
Number of subjects: 236